Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 560 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to... August 6, 2021 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma November 14, 2024 Load more HOT NEWS Building a Support Community During Cancer: “Your Stories” Podcast Apple Season is Here! Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... Foodie Friday: What to do with all these zucchini?
